Leptospirosis Market - Growth, Trends, COVID -19 Impact, and Forecasts (2022 - 2027)

The leptospirosis market is segmented by Treatment Type (Penicillin, Ampicillin, Doxycycline, Ceftriaxone, Azithromycin, Tetracycline and Others), Diagnosis (Microscopic Agglutination Test, Complete Blood Count, Urinalysis, and Others), and End Users (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

leptospirosis Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.1 %
leptospirosis Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The leptospirosis market is expected to register a CAGR of 6.1% over the forecast period, 2022-2027.

The COVID-19 outbreak has had a significant impact on the growth of the leptospirosis market. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in the diagnosis and treatment of leptospirosis as hospital visits were limited to COVID-19 positive cases or other emergency cases, and complete lockdowns were imposed in various countries to stop the spread of the virus. Thus, during the pandemic, several manufacturing and supply chain activities were disrupted, ultimately hindering the market's growth in the pandemic’s preliminary phase. However, several countries reported growth in the number of leptospirosis cases amid the outbreak. For instance, as per the article titled "Coinfection of leptospirosis and coronavirus disease 2019: A retrospective case series from a coastal region in South India" published in PubMed.gov in September 2022, leptospirosis and coronavirus infection were endemic in the coastal regions of South India during the monsoon season of 2020. The purpose of this study was to examine the clinical characteristics and prognoses of patients who had both infections. All COVID-19 patients whose leptospirosis diagnoses were confirmed by an immunoglobulin M enzyme-linked immunosorbent assay had their medical records retrospectively reviewed. Between July and November 2020, 24 cases of coinfections were admitted. Similarly, as per another article titled "Dengue and leptospirosis infection during the coronavirus 2019 outbreak in Sri Lanka" published in Transactions of the Royal Society of Tropical Medicine and Hygiene, in September 2021, for the second quarter of 2020 compared to 2019, a considerable decline in dengue fever cases and a conflicting rise in leptospirosis infections were recorded in Sri Lanka. In the second quarter of 2020, 3,404 cases were reported, up from 2,457 cases in the same period in 2019, representing a 38.5 percent increase. Thus, owing to the increasing coinfections amid the pandemic, the market is anticipated to grow over the coming years.

In addition, the growing prevalence of leptospirosis, surge in R&D activities for the identification of new treatments, and increasing initiatives and awareness about bacterial diseases and prevention are expected to boost the growth of the market. For instance, a review article titled, "Role of Diagnostics in Epidemiology, Management, Surveillance, and Control of Leptospirosis" published in the Pathogens Journal in March 2022, stated that human leptospirosis infection is a leading and neglected source of morbidity and mortality, with more than 1 million cases and approximately 60,000 deaths per year. Likewise, in a report titled, "Assessing rodents as carriers of pathogenic Leptospira species in the U.S. Virgin Islands and their risk to animal and public health", published in January 2022, a sampling of United States Virgin Islands (USVI) rodents determined that 45.7% (64/140) were carriers of pathogenic Leptospira species. Exposure to rodents is associated with an increased risk of leptospirosis. The study also revealed that acute infections are more common in low-resource, tropical and subtropical locations where outbreaks can occur after natural disasters such as hurricanes and heavy rainfall and flooding. Such a rise in the target population is likely to have a positive impact on the market's growth.

Moreover, in July 2020, WHO collaborated with the Global Leptospirosis Environmental Action Network (GLEAN), Food and Agriculture Organization (FAO), Indonesia Epidemiology Association, and Indonesia Parasitic Control Association to assist the Ministry of Health in conducting a series of four webinars on leptospirosis prevention and control in Indonesia in order to explore relevant solutions and the implementation of the one health approach to fight leptospirosis during the COVID-19 pandemic.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the lack of awareness about leptospirosis infection within the population is likely to impede the market growth.

Scope of the Report

As per the scope of the report, leptospirosis is a zoonotic illness that can spread from animals to humans, and it can infect both people and animals. Leptospirosis can be acquired through the nose, mouth, eyes, or skin abrasions when a person encounters water that has been polluted by the infected animals. The leptospirosis market is segmented by Treatment Type (Penicillin, Ampicillin, Doxycycline, Ceftriaxone, Azithromycin, Tetracycline, and Others), Diagnosis (Microscopic Agglutination Test, Complete Blood Count, Urinalysis, and Others), and End Users (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for five different major regions, globally.

By Treatment Type
Penicillin
Ampicillin
Doxycycline
Ceftriaxone
Azithromycin
Tetracycline
Others
By Diagnosis
Microscopic Agglutination Test
Complete Blood Count
Urinalysis
Others (Blood Culture and Liver Enzymes, among others)
By End Users
Hospitals
Speciality Clinics
Other End Users
Geography
North America
Europe
Asia-Pacific
Middle East and Africa
South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Penicillin Segment is Expected to Witness Growth Over the Forecast Period

By treatment type, the penicillin segment is expected to register a significant growth rate throughout the forecast period owing to factors such as the surge in research and development and an increase in the prevalence of leptospirosis; the advantages of penicillin treatment over other treatments; and growing commercial availability. For instance, according to a research study titled, "Insight into the Structure, Functions, and Dynamics of the Leptospira Outer Membrane Proteins with Pathogenicity" published in MDPI in March 2022, early penicillin therapy is efficient and can significantly reduce the risk of patients suffering from multiple organ failure. Furthermore, intravenous (IV) penicillin is advised for severe leptospirosis.

Likewise, the growing number of outbreaks is likely to have a positive impact on the segment’s growth. For instance, in July 2022, the southern district of Lindi, Tanzania, identified 20 cases of leptospirosis, a bacterial infection that has killed three people. Test findings from samples of patients in Ruangwa, according to health minister Ummy Mwalimu, were positive for the condition. Moreover, in December 2021, the Centers for Disease Control and Prevention (CDC) launched two global networks and awarded USD 22 million to nearly 30 organizations around the world to combat antimicrobial resistance and infectious diseases. Leptospirosis was one of the infectious diseases being considered.

Thus, owing to the abovementioned factors, the segment is estimated to project substantial growth over the analysis period.

leptospirosis Market Trends

North America is Expected to Dominate the Leptospirosis Market Over the Forecast Period

North America is expected to hold a significant share of the leptospirosis market owing to the surge in leptospirosis epidemics, growing awareness regarding bacterial infections, the presence of drug manufacturers, and an upsurge in natural disasters resulting in bacterial contamination and zoonosis. For instance, the data provided by the Centers for Disease Control and Prevention in 2022 stated that the United States had experienced leptospirosis outbreaks owing to floods in Hawaii, Florida, and Puerto Rico in 2021.

Furthermore, a study titled, "Leptospirosis in the elderly: the role of age as a predictor of poor outcomes in hospitalized patients" published in the National Library of Medicine in 2020 detailed that the hospitalization rate due to leptospirosis in the United States was higher for elderly patients when compared to younger individuals, especially those less than 20 years of age. Additionally, an article titled "Animal Zoonotic Related Diseases" published in STATPEARLS in May 2022 stated that zoonoses constitute 61% of infectious diseases, 75% of emerging infectious diseases, and 80% of potential bioterrorism pathogens. According to the same source, Leptospira is the most common zoonotic disease worldwide, and most cases in the United States are observed in Hawaii in farmers, veterinarians, and surfers.

Therefore, owing to the aforementioned factors, the growth of the leptospirosis market is anticipated to be boosted in the North American region.

leptospirosis Market Growth

Competitive Landscape

The leptospirosis market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold the market share and are well known. Some of the key players within the market include GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Cipla Inc, Pfizer Inc, Johnson & Johnson Services Inc, AstraZeneca, Baxter, Abbott, Sun Pharmaceutical Industries Limited, and Lupin, among others.

Recent Developments

In June 2021, Hikma Pharmaceuticals Plc launched Doxycycline for Injection, USP, 100mg, in the United States. Doxycycline is an antibiotic used to treat or prevent infections that are definitely or highly believed to be brought on by bacteria that are sensitive. 

In January 2020, Boehringer Ingelheim launched Polyflex, which is an injectable suspension of ampicillin, available in vials containing 25 g of ampicillin trihydrate.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Prevalence of Leptospirosis

      2. 4.2.2 Surge In Research and Development Activities for Bacterial Infections

    3. 4.3 Market Restraints

      1. 4.3.1 Unawareness about Leptospirosis Infections

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Treatment Type

      1. 5.1.1 Penicillin

      2. 5.1.2 Ampicillin

      3. 5.1.3 Doxycycline

      4. 5.1.4 Ceftriaxone

      5. 5.1.5 Azithromycin

      6. 5.1.6 Tetracycline

      7. 5.1.7 Others

    2. 5.2 By Diagnosis

      1. 5.2.1 Microscopic Agglutination Test

      2. 5.2.2 Complete Blood Count

      3. 5.2.3 Urinalysis

      4. 5.2.4 Others (Blood Culture and Liver Enzymes, among others)

    3. 5.3 By End Users

      1. 5.3.1 Hospitals

      2. 5.3.2 Speciality Clinics

      3. 5.3.3 Other End Users

    4. 5.4 Geography

      1. 5.4.1 North America

      2. 5.4.2 Europe

      3. 5.4.3 Asia-Pacific

      4. 5.4.4 Middle East and Africa

      5. 5.4.5 South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline plc

      2. 6.1.2 Novartis AG

      3. 6.1.3 AbbVie Inc.

      4. 6.1.4 Cipla Inc.

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 Lupin Limited

      7. 6.1.7 Abbott Laboratories

      8. 6.1.8 Johnson & Johnson Services Inc.

      9. 6.1.9 AstraZeneca plc

      10. 6.1.10 Baxter International Inc.

      11. 6.1.11 Sun Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Leptospirosis Market market is studied from 2019 - 2027.

The Global Leptospirosis Market is growing at a CAGR of 6.1% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Cipla Inc, Pfizer Inc are the major companies operating in Global Leptospirosis Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!